The Eligible But Under-Tested: Genomic Medicine in 2026 with Damon Hostin, Illumina
Damon Hostin of Illumina discusses the current adoption of genomic testing, noting it has entered the standard of care in some areas but remains incomplete, with many eligible patients still under-tested. The value of a genome compounds over time with growing databases and new…